🌐 English में देखें
I
💳 पेड
🇮🇳 हिंदी
Immunai
Immunai पर जाएं
immunai.com
Immunai क्या है?
Immunai is an AI biotech company that decodes the human immune system at single-cell resolution, using multi-omic data, machine learning, and functional genomics to generate insights that guide immunotherapy development and oncology drug discovery. Its core platform, AMICA-OS, integrates one of the largest clinical immunology databases in the industry — built from harmonized single-cell data across internal experiments, academic partnerships, and public datasets — with foundation AI models trained specifically on immune biology.
In April 2025, Immunai partnered with the Parker Institute for Cancer Immunotherapy to build what the organizations describe as the world's largest patient-centric single-cell dataset, drawing from 3,700 blood samples across 1,070 patients treated with immune checkpoint inhibitors. In January 2026, Bristol Myers Squibb signed a separate multi-year partnership focused on analyzing clinical immune data to clarify mechanisms of action and identify patient subgroups. In May 2026, Immunai expanded its oncology collaboration with AstraZeneca for the third time, with Immunai eligible to receive up to $37.5 million over 2026 and 2027 — signaling continued confidence from one of the world's largest biopharmaceutical companies in the platform's clinical utility.
Immunai is not a general bioinformatics tool or a cloud-based sequencing service. Academic labs without access to matched clinical patient samples or organizations looking for a general-purpose single-cell analysis workflow will find the platform's strength — integrating patient sample data with the AMICA immune cell atlas — underutilized without the clinical data context that makes its machine learning models most predictive.
In April 2025, Immunai partnered with the Parker Institute for Cancer Immunotherapy to build what the organizations describe as the world's largest patient-centric single-cell dataset, drawing from 3,700 blood samples across 1,070 patients treated with immune checkpoint inhibitors. In January 2026, Bristol Myers Squibb signed a separate multi-year partnership focused on analyzing clinical immune data to clarify mechanisms of action and identify patient subgroups. In May 2026, Immunai expanded its oncology collaboration with AstraZeneca for the third time, with Immunai eligible to receive up to $37.5 million over 2026 and 2027 — signaling continued confidence from one of the world's largest biopharmaceutical companies in the platform's clinical utility.
Immunai is not a general bioinformatics tool or a cloud-based sequencing service. Academic labs without access to matched clinical patient samples or organizations looking for a general-purpose single-cell analysis workflow will find the platform's strength — integrating patient sample data with the AMICA immune cell atlas — underutilized without the clinical data context that makes its machine learning models most predictive.
संक्षेप में
Immunai is an AI Tool that applies single-cell genomics and foundation AI models to the specific challenge of immunotherapy development, using its AMICA-OS platform to turn raw clinical sample data into mechanistic insights about immune response, patient stratification, and drug target identification. Its 170-person team and nearly $270 million raised position it as one of the better-capitalized AI immunology platforms, with active multi-year partnerships at AstraZeneca and Bristol Myers Squibb demonstrating real-world adoption at pharmaceutical scale.
मुख्य विशेषताएं
AMICA™ Platform
AMICA-OS integrates the world's largest immune-focused, harmonized single-cell database with advanced foundation AI models of the immune system. The platform combines data from internal experiments, academic partnerships including the Parker Institute for Cancer Immunotherapy, and public datasets at single-cell resolution — providing the immune context that makes AI predictions biologically interpretable.
Data Engineering
Manages multi-omic data generation at scale, including CITE-seq covering approximately 1,500 genes per cell and 80-plus surface proteins alongside TCR sequencing, with full quality control and annotation. The company's New York laboratory at 430 East 29th Street processes clinical patient samples directly from pharma partner biobanks as the starting point for every AMICA analysis.
Machine Learning
The ImmunoDynamics Engine (IDE) applies AMICA ONE, a transformer-based model identifying correlations of biological interest, and AMICA REASON, an explainability module that provides mechanistic context for each insight. Immunai's CEO describes explainability as a primary investment area because insights that cannot be explained do not drive clinical decisions in practice.
Functional Genomics and Experimental Immunology
Combines computational predictions with wet-lab experimental validation, enabling Immunai to test mechanistic hypotheses generated by AMICA against actual immune cell behavior — bridging the gap between computational insight and experimental confirmation that pure bioinformatics platforms cannot close.
In Vitro Model Systems
Supports simulation and experimental testing of immune responses in controlled laboratory conditions, allowing rapid hypothesis validation before committing to expensive in vivo experiments. This capability accelerates the decision cycle between computational prediction and experimental evidence.
फायदे और नुकसान
✅ फायदे
- Innovative Technology — The combination of CITE-seq multi-omic profiling at single-cell resolution with AMICA ONE transformer models and the AMICA REASON explainability layer produces immune insights that connect molecular-level observations to clinical outcomes — a depth of biological interpretability that standard bioinformatics pipelines do not achieve.
- Comprehensive Analysis — Single-cell resolution analysis reveals immune cell subset heterogeneity, activation states, and functional phenotypes invisible to bulk RNA sequencing approaches. This granularity is particularly critical for identifying rare immune cell populations that drive treatment response or toxicity in checkpoint inhibitor and cell therapy programs.
- Speed in Discovery — Integrating patient sample processing, AMICA database comparison, and IDE machine learning into a single workflow compresses the timeline from sample to actionable insight — enabling Immunai's pharma partners to make target and patient stratification decisions in weeks rather than the months that sequential manual analysis requires.
- Strategic Partnerships — Active multi-year collaborations with AstraZeneca expanded three times, Bristol Myers Squibb, and the Parker Institute for Cancer Immunotherapy provide both validation of the platform's clinical utility and a continuously growing patient sample database that improves model accuracy across all subsequent analyses.
❌ नुकसान
- Complex Technology — Effective use of AMICA-OS requires expertise in single-cell immunology, multi-omic data interpretation, and clinical trial biomarker strategy. Organizations without dedicated computational immunologists and translational scientists on staff cannot fully utilize the platform's analytical depth without extensive support from Immunai's team.
- Specialized Application — Immunai's platform is optimized specifically for immune system biology in oncology, autoimmunity, and related therapeutic areas. Organizations working outside immunology — in metabolic disease, cardiovascular research, or CNS programs without an immune component — will find limited applicability for their primary research questions.
- High Investment in Technology — Enterprise partnership agreements, custom sequencing programs, and AMICA-OS integration represent significant financial and organizational commitments. The platform is not available as a self-service tool, which limits access to organizations capable of structuring multi-year collaboration agreements with Immunai's commercial team.
विशेषज्ञ की राय
For biopharmaceutical organizations running immuno-oncology programs with clinical patient samples sitting in biobanks, Immunai converts that underutilized asset into mechanistic immune insights that inform target selection, dose optimization, and patient stratification — capabilities that manual single-cell analysis workflows cannot deliver at the same speed or scale. Access is limited to institutional partnerships rather than self-service deployment.
अक्सर पूछे जाने वाले सवाल
AMICA-OS is Immunai's AI operating system for the human immune system. It integrates one of the largest clinical immunology databases at single-cell resolution with foundation AI models, generating mechanistic insights for biomarker discovery, patient stratification, dose optimization, and mechanism-of-action analysis in oncology and immunotherapy drug development programs.
AstraZeneca has expanded its collaboration with Immunai three times, with the latest agreement making Immunai eligible for up to $37.5 million over 2026-2027. Bristol Myers Squibb signed a multi-year partnership in January 2026 focused on clinical immune data analysis. The Parker Institute for Cancer Immunotherapy joined in a 2025 collaboration to build the world's largest patient-centric single-cell cancer immunotherapy dataset.
Immunai offers the Grand Collaboration Initiative for Single-Cell Immune Profiling, providing free CITE-seq sequencing for 100-1,000 patient samples to academic labs studying cancer, autoimmunity, and immunotherapy. Data is returned with quality control and annotations. Researchers interested should contact Immunai directly, as eligibility requires study design review and sample volume qualification.
Immunai's platform is specialized for immune biology in oncology, autoimmunity, and immunotherapy. Programs outside immunology — CNS, cardiovascular, or metabolic disease without an immune component — will not benefit from AMICA's immune cell atlas or the IDE's immunology-specific analytical framework. Organizations also need access to clinical patient samples as the starting material for analysis.